(0.08%) 5 521.50 points
(0.13%) 39 895 points
(0.17%) 19 784 points
(-0.06%) $81.58
(0.68%) $2.83
(-0.27%) $2 338.10
(0.08%) $29.55
(0.43%) $1 006.10
(0.05%) $0.932
(-0.08%) $10.52
(0.01%) $0.788
(-0.81%) $87.28
0.00% $ 0.910
Live Chart Being Loaded With Signals
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease...
Stats | |
---|---|
Dzisiejszy wolumen | 46 471 |
Średni wolumen | 129 270 |
Kapitalizacja rynkowa | 56.09M |
EPS | $-0.300 ( Q1 | 2024-05-14 ) |
Następna data zysków | ( $-0.310 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.590 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (0.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-21 | Countouriotis Athena | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Gowen Maxine | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Kapadia Sandip | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Islam Saqib | Buy | 47 693 | Director Stock Option (right to buy) |
2024-05-21 | Sondhi Dolan | Buy | 39 092 | Director Stock Option (right to buy) |
INSIDER POWER |
---|
82.55 |
Last 97 transactions |
Buy: 8 193 316 | Sell: 441 732 |
Wolumen Korelacja
Passage Bio Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
REYN | 0.88 |
POWL | 0.873 |
VEON | 0.861 |
CLBT | 0.86 |
CFLT | 0.854 |
MRUS | 0.851 |
FWRG | 0.846 |
EQ | 0.842 |
MEDP | 0.837 |
MACK | 0.835 |
10 Najbardziej negatywne korelacje | |
---|---|
CYAN | -0.857 |
CAR | -0.831 |
WTER | -0.829 |
SSRM | -0.829 |
FINW | -0.827 |
BIOL | -0.826 |
EGAN | -0.821 |
KRKR | -0.818 |
VREX | -0.813 |
BLKB | -0.809 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Passage Bio Inc Korelacja - Waluta/Towar
Passage Bio Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-3.72M (0.00 %) |
EPS: | $-1.860 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-3.68M (0.00 %) |
EPS: | $-2.51 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-3.48 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej